期刊文献+

肿瘤蛋白质组学:过去、现在和将来 被引量:8

Tumor Proteomics:The Past,Present and Future
下载PDF
导出
摘要 将蛋白质组学的技术方法应用到肿瘤生物学的研究中,产生了一门新学科——肿瘤蛋白质组学。它以寻找肿瘤标志物为目的,以蛋白质组学方法为手段,结合肿瘤分子机制的基础研究与肿瘤检测、诊断等临床研究,最终产出能应用于临床的肿瘤检测和治疗的蛋白质靶标。肿瘤蛋白质组学经历了表达谱、修饰谱到活性谱的进化过程,在不同的层面上揭示肿瘤可能的致病机制。本文概述了近年来在常见的恶性肿瘤中进行的肿瘤蛋白质组研究,应用各种蛋白质组技术方法,如二维凝胶电泳(two-dimensional gel electrophresis,2DE)、细胞培养稳定同位素标记技术(stable isotope labeling by amino acid in cell culture,SILAC)、基质辅助激光解析(matrix assisted laser desorption/ionization,MALDI)质谱等,找到了大量的蛋白质标志物。将来的挑战在于如何从理论上应用候选标志物解析肿瘤的分子机制,以及从实践上鉴定能真正应用于临床的标志物。 The application of proteomics techniques to tumor biological research promoted the emergence of Tumor Proteomics. Its major goal is to screen biomarkers for tumor detection, diagnosis, prognosis, as well as tumor treatment using proteomics technologies, such as two dimensional gel electrophoresis (2-DE), stable isotope labeling of amino acid in cell culture (SILAC) and matrix assisted laser desorption/ionization (MALDI). Three stages of tumor proteomics study, including expression proteomics, posttranslation modification proteomics and activity-based proteomics, have shed lights on not only the possible tumor markers but also the underlying mechanisms. We reviewed the methods as well as the achievements of recent tumor proteomics studies on major tumor types. The challenges are to sift out tumor markers for clinical applications, and to reveal novel mechanisms of tumorigenesis that may help to fight this deadly disease.
出处 《癌症》 SCIE CAS CSCD 北大核心 2008年第10期1009-1017,共9页 Chinese Journal of Cancer
关键词 肿瘤蛋白质组学 标志物 Tumor proteomics Biomarkers
  • 相关文献

参考文献75

  • 1Ong S E, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in Cell culture, SILAC, as a simple and accurate approach to expression proteomics [J]. Mol Cell Proteomies, 2002, 1 (5) : 376-386.
  • 2Wingren C, Borrebaeck C A. Antibody microarray analysis of directly labelled complex proteomes [J]. Curr Opin Bioteehnol, 2008,19 ( 1 ) : 55-61.
  • 3Rifai N, Gillette M A, Cart S A. Protein biomarker discovery and validation : the long and uncertain path to clinical utility [J]. Nat Biotechnol, 2006,24(8) :971-983.
  • 4Paulick M G, Bogyo M. Application of activity-based probes to the study of enzymes involved in cancer progression [J]. Curt Opin Genet Dev, 2008,18 (1):97-106.
  • 5Sun W, Xing B, Sun Y, et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues [J]. Mol Cell Proteomics, 2007,6(10) : 1798-1808.
  • 6Hu S, Li Y, Liu G, et al. A protein chip approach for high-throughput antigen identification and characterization [J]. Proteomics, 2007,7 (13) :2151 -2161
  • 7Kanmura S, Uto H, Kusumoto K, et al. Early diagnostic potential for hepotocellular carcinoma using the SELDI ProteinChip system [J].Hepatology, 2007,45(4) :948-956.
  • 8Melle C, Ernst G, Scheibner O, et al. Identification of specific protein markers in microdisseeted hepatoeellular carcinoma [J]. J Proteome Res, 2007,6( 1 ) :306-315.
  • 9Park K S, Kim H, Kim N G, et al. Proteomie analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma [J]. Hepatology, 2002,35(6) : 1459-1466.
  • 10Paradis V, Degas F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases [J]. Hepatology, 2005,41(1):40-47.

同被引文献70

引证文献8

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部